Biopharmaceutical company Medivation agreed to sell to Pfizer for approximately $14 billion. Medivation’s portfolio includes XTANDI® (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell.